...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Immune correlates of protection for dengue: State of the art and research agenda
【24h】

Immune correlates of protection for dengue: State of the art and research agenda

机译：登革热保护的免疫相关性：艺术状态和研究议程

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Dengue viruses (DENV1-4) are mosquito-borne flaviviruses estimated to cause up to similar to 400 million infections and similar to 100 million dengue cases each year. Factors that contribute to protection from and risk of dengue and severe dengue disease have been studied extensively but are still not fully understood. Results from Phase 3 vaccine efficacy trials have recently become available for one vaccine candidate, now licensed for use in several countries, and more Phase 2 and 3 studies of additional vaccine candidates are ongoing, making these issues all the more urgent and timely. At the "Summit on Dengue Immune Correlates of Protection", held in Annecy, France, on March 8-9, 2016, dengue experts from diverse fields came together to discuss the current understanding of the immune response to and protection from DENV infection and disease, identify key unanswered questions, discuss data on immune correlates and plans for comparison of results across assays/consortia, and propose a research agenda for investigation of dengue immune correlates, all in the context of both natural infection studies and vaccine trials.
机译：登革热病毒（Denv1-4）是蚊香的黄病毒估计，估计达到4亿感染，每年类似于1亿日登革病例。广泛研究有助于保护和登革热和严重登革热疾病的因素，但仍未完全理解。第3阶段疫苗疗效试验的结果最近可用于一个疫苗候选人，现在在几个国家使用许可，更多的阶段2和3次疫苗候选人的研究正在进行中，使这些问题变得更加紧迫和及时。在法国Annecy举行的“登革热免疫相关概述”中，2016年3月8日至9日，来自不同领域的登革热专家聚集在一起，讨论目前对免疫应对和免受DENV感染和疾病的理解，确定关键的未答复问题，讨论关于免疫相关性的数据，并计划对分析/联盟的结果进行比较，并提出了一项研究议程，用于调查登革热免疫相关性，所有这些议程都在自然感染研究和疫苗试验中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号